Dmitrij Hristodorov

Summary

Affiliation: RWTH Aachen
Country: Germany

Publications

  1. pmc Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen 52074, Germany
    Toxins (Basel) 4:676-94. 2012
  2. doi Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model
    Manal Amoury
    Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Pauwelsstr 20, 52074 Aachen, Germany
    Cancer Lett 372:201-9. 2016
  3. doi A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein
    Manal Amoury
    Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Germany
    Int J Cancer 139:916-27. 2016
  4. doi Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Br J Haematol 164:251-7. 2014
  5. doi Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital, RWTH Aachen University, Aachen, Germany
    Immunol Cell Biol 94:470-8. 2016
  6. doi The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia
    Radoslav Mladenov
    Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, RWTH Aachen University Clinic, Aachen, Germany
    Int J Cancer 137:2729-38. 2015
  7. doi Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein
    Hannes Brehm
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Cancer Lett 365:149-55. 2015
  8. doi Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells
    Sonja Schiffer
    Department of Experimental Medicine and Immunotherapy, RWTH Aachen, Institute for Applied Medical Engineering, Aachen, Germany Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany
    Cancer Lett 341:178-85. 2013
  9. doi EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Mol Cancer Ther 13:2194-202. 2014

Collaborators

  • Stefan Barth
  • Thomas Nachreiner
  • Christoph Stein
  • Radoslav Mladenov
  • Rainer Fischer
  • Manal Amoury
  • Theophilus Thepen
  • Alessa Pardo
  • Hannes Brehm
  • Wijnand Helfrich
  • Fabian Kiessling
  • Anh Tuan Pham
  • Katharina Kolberg
  • Ahmad F Hussain
  • Stefano Di Fiore
  • Judith Niesen
  • Edgar Jost
  • Sonja Schiffer
  • Georg Fey
  • Michael Schwenkert
  • Bernhard Stockmeyer
  • Mehmet K Tur
  • Fabian Kreutzer
  • Tobias Blume
  • Christian Cremer
  • Lea Hein
  • Tim Henrik Brümmendorf
  • Tim Stroisch
  • Michael Huhn
  • Theo Thepen
  • Soriba Letzian

Detail Information

Publications9

  1. pmc Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen 52074, Germany
    Toxins (Basel) 4:676-94. 2012
    ..In this review, we focus on the role of different polarized macrophages and the potential of CD64-based IT to intervene in the process of chronic inflammation...
  2. doi Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model
    Manal Amoury
    Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Pauwelsstr 20, 52074 Aachen, Germany
    Cancer Lett 372:201-9. 2016
    ..Taken together, our results indicate that GbR201K-αEpCAM(scFv) is a promising novel targeted therapeutic for the treatment of TNBC. ..
  3. doi A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein
    Manal Amoury
    Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Germany
    Int J Cancer 139:916-27. 2016
    ..Taken together, this preclinical proof of concept study confirms the potential clinical value of αCSPG4(scFv)-MAP as a novel targeted approach for the elimination of CSPG4-positive TNBC. ..
  4. doi Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Br J Haematol 164:251-7. 2014
    ..Our data present a novel approach for the treatment of CD30(+) lymphomas, combining the binding specificity of a target-specific antibody fragment with the selective cytotoxicity of MAPT towards proliferating lymphoma cells. ..
  5. doi Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital, RWTH Aachen University, Aachen, Germany
    Immunol Cell Biol 94:470-8. 2016
    ....
  6. doi The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia
    Radoslav Mladenov
    Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, RWTH Aachen University Clinic, Aachen, Germany
    Int J Cancer 137:2729-38. 2015
    ..We conclude that CD89-specific targeting of leukemia cell lines can be achieved in vitro and that the efficient elimination of leukemic primary cells supports the potential of CD89-ETA' as a potent, novel immunotherapeutic agent. ..
  7. doi Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein
    Hannes Brehm
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Cancer Lett 365:149-55. 2015
    ..We also confirmed that scFv35-MAP induces apoptosis in FL-OH1 and RD cells. The in vivo potential of scFv35-MAP will need to be considered in further studies. ..
  8. doi Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells
    Sonja Schiffer
    Department of Experimental Medicine and Immunotherapy, RWTH Aachen, Institute for Applied Medical Engineering, Aachen, Germany Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany
    Cancer Lett 341:178-85. 2013
    ..In conclusion, granzyme M is a promising new cell-death inducing component for hCFPs because it specifically and efficiently kills target cells when fused to a targeting component...
  9. doi EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein
    Dmitrij Hristodorov
    Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
    Mol Cancer Ther 13:2194-202. 2014
    ..In conclusion, our data suggest that anti-EpCAM(scFv)-MAP may be of therapeutic value for the targeted elimination of EpCAM(+) carcinomas...